Daily Respiratory Research Analysis
Three studies stand out today: an updated meta-analysis quantifying the substantial and shifting burden of RSV among children in Western Pacific and Southeast Asia; a registry-based biomarker study showing pre-treatment MMP7 predicts progression and mortality in antifibrotic-treated idiopathic pulmonary fibrosis; and a prospective multicenter analysis demonstrating that bacterial co-infection markedly increases severity and ICU use in RSV-hospitalized infants.
Summary
Three studies stand out today: an updated meta-analysis quantifying the substantial and shifting burden of RSV among children in Western Pacific and Southeast Asia; a registry-based biomarker study showing pre-treatment MMP7 predicts progression and mortality in antifibrotic-treated idiopathic pulmonary fibrosis; and a prospective multicenter analysis demonstrating that bacterial co-infection markedly increases severity and ICU use in RSV-hospitalized infants.
Research Themes
- RSV epidemiology and prevention policy
- Biomarkers for fibrotic lung disease progression
- Infection interactions and pediatric respiratory severity
Selected Articles
1. Trends in Proportions of Respiratory Syncytial Virus Infections Among Reported Respiratory Tract Infection Cases in Children Aged 0 to 5 Years in Western Pacific and Southeast Asia Regions: A Systematic Review and Meta-Analysis.
In 173 eligible studies across 1970–2020, the pooled proportion of RSV among all acute respiratory tract infections in children 0–5 years was 18.7% and 28.7% among lower RTIs, peaking in the 1980s with subsequent declines. Substantial heterogeneity and country-level variation were observed, highlighting persistent RSV burden and regional prioritization needs.
Impact: Provides an updated, region-specific quantification of pediatric RSV burden to inform immunization and prophylaxis policies as new RSV vaccines and monoclonals roll out.
Clinical Implications: Supports planning for RSV prevention (maternal vaccination or infant monoclonal antibody use), hospital preparedness during peak seasons, and tailored surveillance in high-burden countries.
Key Findings
- Across 173 studies (1970–2020), RSV accounted for 18.7% of all ARTIs and 28.7% of LRTIs in children ≤5 years.
- The proportion peaked in the 1980s (33.4%) and declined through the 2010s (20.1%).
- Marked country-level variability with highest proportions in Myanmar and New Zealand, followed by Bhutan, Lao PDR, and Vietnam.
Methodological Strengths
- Comprehensive systematic review with random-effects meta-analysis over five decades
- Clear inclusion criteria focusing on RTI/ILI in children ≤5 years and regional stratification
Limitations
- Heterogeneity in study designs, diagnostics, and time periods
- Potential publication and reporting biases across regions and decades
Future Directions: Link regional burden estimates to cost-effectiveness models for maternal vaccination and infant monoclonal strategies, and update with post-2020 data reflecting NPIs and RSV immunization programs.
BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of bronchiolitis and pneumonia in children globally. This study aimed to incorporate new data to update estimates of RSV burden in children through 5 years of age in Western Pacific and Southeast Asia Regions. METHODS: A systematic review and meta-analysis were conducted to examine the proportion of RSV among cases of respiratory tract infection (RTI) in children in Western Pacific and Southeast Asia Regions using random effects models. Studies were eligible if they met the follow
2. Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.
In two cohorts (n=98), higher pre-treatment serum MMP7 identified IPF patients who progressed despite antifibrotic therapy, with AUC 0.74–0.81. Elevated MMP7 predicted 12‑month progression and overall mortality, and multi-biomarker panels further improved prognostication beyond MMP7 or GAP alone.
Impact: Offers a pragmatic serum biomarker to risk‑stratify antifibrotic‑treated IPF patients and tailor monitoring and trial enrichment strategies.
Clinical Implications: Baseline MMP7 can guide surveillance intensity, earlier transplant referral consideration, and selection for add‑on therapies or trials; combining MMP7 with clinical indices (GAP) may refine mortality risk.
Key Findings
- Baseline MMP7 was significantly higher in progressive IPF across two cohorts and best discriminated progression (AUC 0.74–0.81).
- Elevated MMP7 predicted 12-month progression (OR 1.53) and overall mortality (HR 1.27).
- A multi-biomarker panel (MMP7, ICAM-1, CHI3L1, CA125) outperformed MMP7 alone; GAP plus biomarkers improved 3-year mortality prediction.
Methodological Strengths
- Prospective registry sampling with predefined progression endpoints (FVC, DLCO, death)
- Replication across two cohorts and use of multivariable and LASSO modeling
Limitations
- Modest sample size and single-national registry may limit generalizability
- Biomarker thresholds for clinical use were not prospectively validated
Future Directions: Prospective validation of MMP7-based thresholds, integration into treatment algorithms, and testing as an enrichment biomarker for add‑on antifibrotic or anti-inflammatory trials.
BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12-months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients. METHODS: Serum from 98 IPF participants, from the Australian Idiopathic Pulmonary Fibrosis Registry were collected at four time-points over 1 year post-antifibrotic treatment and analysed as two separate cohorts. Patients were stratified as progressive, if they experienced ≥ 10% decline in FVC or ≥ 15% decline in DLCO or were deceased within 1 year of treatment initiation: or otherwise as stable. Ten molecules of interest were measured by ELISAs in patient serum. RESULTS: Baseline MMP7 levels were higher in progressive than stable patients in Cohort 1 (p = 0.02) and Cohort 2 (p = 0.0002). Baseline MMP7 levels also best differentiated progressive from stable patients (Cohort 1, AUC = 0.74, p = 0.02; Cohort 2, AUC = 0.81, p = 0.0003). Regression analysis of the combined cohort showed that elevated MMP7 levels predicted 12-month progression (OR = 1.530, p = 0.010) and increased risk of overall mortality (HR = 1.268, p = 0.002). LASSO regression identified a multi-biomarker panel (MMP7, ICAM-1, CHI3L1, CA125) that differentiated progression more accurately than MMP7 alone. Furthermore, GAP combined with MMP7, ICAM-1, CCL18 and SP-D was more predictive of 3-year mortality than GAP alone. CONCLUSION: MMP7 along with a multi-biomarker and GAP panel can predict IPF progression and mortality, with the potential for optimising management.
3. RSV-Bacterial Co-Infection Is Associated With Increased Illness Severity in Hospitalized Children - Results From a Prospective Sentinel Surveillance Study.
In 678 hospitalized RSV cases <2 years, 20.4% had potentially pathogenic bacterial co-infection, which was associated with markedly higher ICU admission, longer hospital stays, and a 13-fold risk of severe disease. Findings persisted after adjustment, though differential testing in sicker children may inflate risk estimates.
Impact: Quantifies the clinical penalty of RSV–bacterial co-infection during atypical seasons, informing antibiotic stewardship, vaccination, and hospital resource planning.
Clinical Implications: Consider targeted diagnostics for bacterial co-pathogens in high-risk RSV infants, optimize empiric therapy when clinically indicated, and prioritize prevention strategies reducing bacterial overgrowth.
Key Findings
- Among 678 RSV hospitalizations, 20.4% had potentially pathogenic bacteria detected.
- Co-infection was associated with higher ICU admissions (29.7% vs 3.5%), longer LOS (7 vs 5 days), and a 13.2-fold risk of severe disease.
- Authors note possible overestimation due to greater bacterial testing in sicker children, but multivariable models supported associations.
Methodological Strengths
- Prospective multicenter sentinel design with predefined severity outcomes
- Multivariable regression (linear and log-binomial) to adjust for confounders
Limitations
- Potential differential testing bias for bacterial pathogens in sicker patients
- Lack of standardized bacterial diagnostic methods across sites
Future Directions: Harmonize testing algorithms, evaluate microbiome-informed prevention, and assess the impact of RSV immunization (maternal vaccines/infant mAbs) on bacterial co-infections.
During the autumn/winter respiratory syncytial virus (RSV) epidemics, bacterial co-infection is common and affects the disease severity. We aimed to understand the relationship between RSV-bacterial co-infections and clinical severity since the RSV seasonality change after COVID-19 pandemic. We conducted a prospective, sentinel surveillance study at 20 sites in Portugal in children under 2 years hospitalized with RSV, between April 21 and January 23. Effect of co-infection with potentially pathogenic bacteria (PPB) on the length of hospitalization and disease severity was investigated using multivariate linear and log-binomial regression models. Among 678 RSV hospitalizations, 67.4% occurred in children under 6 months and 15.3% in preterm; 20.4% tested positive for PPB; median length of hospitalization was 5 days (IQR: 3-7days). Children coinfected with PPB had a higher rate of ICU admission (29.7% vs. 3.5%, p < 0.001), resulting in more prolonged hospitalizations (7 vs. 5 days, p < 0.001) and a 13-fold risk of having severe disease (RR: 13.2, 95% CI:7.3-23.9). RSV-bacterial co-infection was associated with increased length of hospitalization and severe illness during off-season epidemics. This risk is probably overestimated, as laboratory testing for bacterial infections is usually higher in severely ill-appearing children. Measures to prevent outgrowth of pathogenic bacteria within the respiratory tract should be discussed.